

**OBJECTIVE**—Insulin resistance in skeletal muscle is an early phenomenon in the pathogenesis of type 2 diabetes. Studies of insulin resistance usually are highly focused. However, approaches that give a more global picture of abnormalities in insulin resistance are useful in pointing out new directions for research. In previous studies, gene expression analyses show a coordinated pattern of reduction in nuclear-encoded mitochondrial gene expression in insulin resistance. However, changes in mRNA levels may not predict changes in protein abundance. An approach to identify global protein abundance changes involving the use of proteomics was used here.

**RESEARCH DESIGN AND METHODS**—Muscle biopsies were obtained basally from lean, obese, and type 2 diabetic volunteers (n = 8 each); glucose clamps were used to assess insulin sensitivity. Muscle protein was subjected to mass spectrometry–based quantification using normalized spectral abundance factors.

**RESULTS**—Of 1,218 proteins assigned, 400 were present in at least half of all subjects. Of these, 92 were altered by a factor of 2 in insulin resistance, and of those, 15 were significantly increased or decreased by ANOVA (P < 0.05). Analysis of protein sets revealed patterns of decreased abundance in mitochondrial proteins and altered abundance of proteins involved with cytoskeletal structure (desmin and alpha actinin-2 both decreased), chaperone function (TCP-1 subunits increased), and proteasome subunits (increased).

**CONCLUSIONS**—The results confirm the reduction in mitochondrial proteins in insulin-resistant muscle and suggest that changes in muscle structure, protein degradation, and folding also characterize insulin resistance. *Diabetes* 59:33–42, 2010

Skeletal muscle insulin resistance is critical to the pathogenesis of type 2 diabetes (1) and the metabolic syndrome (2). Numerous investigations over the past 4 decades have revealed an array of abnormalities in insulin action in skeletal muscle of obese and type 2 diabetic patients and have led to a better understanding of the molecular pathways involved in insulin and cytokine signaling, inflammation, and gene expression in skeletal muscle. In insulin-resistant muscle, there are defects in insulin signaling (3,4), activities of metabolic enzymes (5,6), and regulation of gene expression (6–9), among others.

Often these studies are highly focused. However, several groups have used approaches that give a more global picture of abnormalities, such as oligonucleotide microarray analysis (7–9). The value of global analysis is that it can yield a view of patterns of changes in pathways and generate new hypotheses that serve as foci for more detailed analysis. Global gene expression analyses conducted in insulin-resistant muscle have shown a pattern of reduced expression of nuclear-encoded mitochondrial genes (7–9). Such findings have spurred new avenues of research and fit well with observations of mitochondrial dysfunction in insulin resistance (10).

However, changes in mRNA levels for a gene may not be mirrored by changes in abundance of the proteins encoded by that gene, which are a closer reflection of the level of activity of a biological pathway. The advent of sensitive and accurate mass spectrometers has made mass spectrometry a valuable tool for biologists interested in protein identification and regulation of protein abundance in complex biological mixtures. Mass spectrometry–based proteomics also is a valuable tool for quantifying differences in protein abundance between, for example, cells cultured in vitro under different conditions or treatments (11–14). Assessment of differences in protein abundance using mass spectrometry analysis of human tissues, where in vivo stable isotope labeling of proteins is impractical, presents special challenges (15–18).

The challenge of comparative proteomics in small human tissue samples has resulted so far in studies that have revealed only a few differences in protein abundance in insulin-resistant muscle (18–20). These challenges were addressed here through the use of an initial separation technique of one-dimensional SDS-polyacrylamide gels, with protein assignment using high-performance liquid chromatography–electrospray ionization–tandem mass spectrometry (HPLC-ESI-MS/MS) and with quantification using a normalized spectral abundance factor (NSAF) method (21–23). The purpose of this study was to develop a global view of protein abundance changes in insulin resistance, in order to provide data that can serve as a basis for generation of novel hypotheses concerning the molecular mechanisms of insulin resistance. Using these techniques, we assigned a total of 1,218 proteins in small percutaneous muscle biopsies taken from metabolically characterized lean and obese non-diabetic volunteers and type 2 diabetic patients. We used normalized spectral abundance factor methods to compare the abundance of

From the 1Center for Metabolic Biology, Arizona State University, Tempe, Arizona; the 2Department of Kinesiology, Arizona State University, Tempe, Arizona; the 3Harrington Department of Bioengineering, Arizona State University, Tempe, Arizona; the 4Diabetes Research Centre, Department of Endocrinology, Odense University Hospital, Odense, Denmark; and the 5School of Life Sciences, Arizona State University, Tempe, Arizona. Corresponding author: Lawrence J. Mandarino, lawrence.mandarino@asu.edu.

Received 19 February 2009 and accepted 3 October 2009. Published ahead of print at http://diabetes.diabetesjournals.org on 15 October 2009. DOI: 10.2337/db09-0214.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
400 of the proteins that were assigned in at least half of all subjects studied. These analyses reveal unexpected new patterns of changes in protein abundance in insulin-resistant muscle, including alterations in abundance of proteins involved in cytoskeletal structure and assembly and increases in proteasome and chaperone subunit abundance.

RESEARCH DESIGN AND METHODS

Lean nondiabetic control subjects, obese nondiabetic subjects, and patients with type 2 diabetes (n = 8 each) were studied. Studies were approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio and Arizona State University. After giving informed written consent, each volunteer underwent a medical history, physical examination, screening laboratory tests, and a 75-g oral glucose tolerance test and underwent a euglycemic-hyperinsulinemic clamp with basal muscle biopsies as described (3,24,25). Complete details are provided in the online appendix, which is available at http://diabetes.diabetesjournals.org/cgi/content/full/db09-0214/DC1.

Gel electrophoresis and mass spectrometry analysis. Muscle lysate proteins (80 μg total protein) were separated on 4–20% linear gradient SDS polyacrylamide gels and processed for mass spectrometry as described (26,27) and as outlined in supplemental Fig. 1 in the online appendix. A complete description of this analysis is provided in the online appendix.

Normalized spectral abundance factors. To quantify protein abundance, NSAFs were used (21–23). Tandem mass spectrometry (MS/MS) spectra assigned to a protein were normalized to the length of the protein (number of amino acids), resulting in a spectral abundance factor (SAF), where SAF = spectrum count/number AA. Each SAF was normalized against the sum of all SAFs in one sample, resulting in the NSAF value. For a protein, i, the normalized spectral abundance factor, NSAF, is calculated by:

\[ \text{NSAF}_i = \frac{\text{SAF}_i}{\sum_{j=1}^{N} \text{SAF}_j} \]

where N is the total number of proteins detected in a sample. Thus, NSAF values allow for direct comparison of a protein’s abundance between individual runs in a fashion similar to microarray data analysis.

Reproducibility and linearity of NSAF method. To determine linearity, varying amounts of BSA tryptic digests (62–250 fmol) were added to 125 fmol cytochrome c digest. Mixtures were analyzed by MS/MS. To assess linearity in a “real life” complex mixture of proteins, muscle biopsy lysates were used. If NSAF provides an accurate reflection of the proportion of any particular protein in a complex protein sample, such as a muscle lysate, then the NSAF for any given protein should be equivalent, no matter how much total protein is analyzed. Complete methods for testing this and a description of the reproducibility experiment are described in the online appendix.

Single protein analysis. Although a large number of proteins were assigned in at least one of 24 subjects who were studied, a series of filters were used to narrow the number of proteins that were used in comparisons among groups. This approach is diagrammed in Fig. 1, with complete details provided in the online appendix.

Differential patterns of protein abundance among groups (protein sets). Differences in NSAF values for a set of proteins among groups were assessed as diagrammed in Fig. 2, with a complete description provided in the online appendix.

To better visualize patterns of differences among groups, protein abundance changes were visualized using the Gene Expression Dynamics Inspector (GEDI) (http://www.childrenshospital.org/research/ingber/GEDI/gedihome.htm) (28). GEDI uses an algorithm that groups individual proteins by patterns of group differences compared with an overall median. Proteins for a particular grouping that are generally lower in abundance than the global mean are depicted in shades of blue, whereas proteins that are increased are depicted in shades of orange and red, similar to a heat map.

Immunoblot analysis. To determine the relationship between NSAF quantification and relative protein abundance determined by immunoblot analysis, two proteins (desmin and alpha actinin-2) that differed significantly among the groups by NSAF analysis were subjected to immunoblot analysis. Only seven of the eight subjects in each group had sufficient muscle protein remaining to perform these analyses. Muscle protein lysates were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed using antibodies against alpha actinin-2 or desmin (both from Santa Cruz Biotechnology, Santa Cruz, CA). PDLIM6 protein was used as a loading control (antibody from Santa Cruz Biotechnology). Blots were quantified by densitometry (VersaDoc 5000; Bio-Rad Laboratories, Hercules, CA).

RESULTS

Clinical and metabolic characteristics. The diabetic subjects had greater fasting plasma glucose and A1C than the obese or lean control subjects (P < 0.01) (Table 1). Obese (P < 0.01) and diabetic (P < 0.05) subjects had a greater BMI. The diabetic subjects were slightly older than the lean group (48 ± 3 vs. 37 ± 4 years, P < 0.05), although the average age of the obese group was intermediate and did not differ significantly from either of the other groups. As expected, the rate of insulin-stimulated glucose uptake was significantly impaired in the obese nondiabetic group and further decreased in the diabetic subjects.

Linearity and reproducibility of NSAF technique. The relationship between the proportion of BSA spectra in a mixture of BSA and cytochrome c and BSA concentration fit a linear regression (r² = 0.90, y = 3.23x − 0.19). Using a complex mixture of proteins (muscle lysate) over a fourfold concentration range (30–120 μg protein), there was a linear relationship between NSAF values. The regression equations for these three comparisons (30 vs. 60, 30 vs. 120, and 60 vs. 120 μg protein) were y = 0.61 − 0.05, y = 1.2lx − 2.49, and y = 1.99x − 2.67, with r² = 0.99, 0.94, and 0.96, respectively. Figure 3 shows the relationship between NSAF values obtained with 30 and 120 μg protein.

To assess reproducibility, three separate portions of a muscle biopsy from a single individual were individually homogenized, run in separate lanes on an SDS gel, and the gel slices trypsinned and processed for high-performance liquid chromatography electrospray ionization–tandem mass spectrometry as described above (20 slices per lane). A total of 334 proteins were assigned that were common to all three biopsy portions, and the average coefficient of variation for these proteins was 22.1%. Power analysis (NQuery Advisor; Statistical Solutions, Saugus, MA) revealed that, using a coefficient of variation of 22.1%, an ANOVA with eight subjects per group has a power of >90% to detect a difference of twofold at the 0.05 level.

Muscle proteome. When the results from all 24 volunteers were combined and redundant results were collapsed, 1,218 proteins were assigned in at least one of the 24 subjects. The complete list of proteins that were assigned is provided as supplemental Table 1, which is available in the online appendix. Proteins that were assigned in at least half (12 of 24) of all participants totaled 400 and are listed in supplemental Table 2. This set of 400 proteins was used for further analysis.

Single protein analysis. Out of 400 proteins that were assigned as present in at least 12 of 24 subjects, a total of 92 of these proteins also were increased or decreased by a factor of two in at least one of the three possible two-group comparisons (obese versus lean, diabetic versus lean, or diabetic versus obese) and are given in supplemental Table 3. Of these 92 proteins, 15 were significantly different among the three groups using one-way ANOVA (P < 0.05, Table 2). Because variances for NSAFs for about half the proteins analyzed were not homogeneous, we also used the nonparametric Kruskal-Wallis test to analyze these data. Of the 15 proteins that significantly differed by ANOVA, 10 also significantly differed by Kruskal-Wallis, and of the other five proteins, two had P values <0.10 and three had P values <0.17.

Of the 15 proteins that differed significantly by ANOVA among the groups, 9 were greater in abundance and 6 were
lower in insulin resistance. Of the six that were lower, three were mitochondrial in location, cytochrome C oxidase VIC precursor (gene name COX6C), coiled-coil-helix-coiled-coil-helix domain-containing protein 3 (gene name CHCHD3), and ubiquinol-cytochrome C reductase complex ubiquinone-binding protein QP-C (gene name UQCRQ), while none of the nine proteins that increased were mitochondrial. Average NSAF values for these proteins are shown in Fig. 4A. The proportion of mitochondrial proteins in the proteins that decreased (3 of 6) was significantly greater than that in proteins that increased in abundance (0 of 9) \((P < 0.05, \text{Fisher exact probability test})\). Three nonmitochondrial proteins that were significantly higher in insulin resistance were proteins that are components of the cytoskeleton or structure of myocytes (alpha actinin 2, myozenin-1, and desmin; Fig. 4B).

This same pattern of decreased mitochondrial proteins also was present in the 77 proteins that differed by a factor of two but were not significant by ANOVA (supplemental Table 3). The \(P\) values determined using both ANOVA and Kruskal-Wallis are shown in this table also. The correlation between \(P\) values for the two methods was 0.76 \((P < 0.01)\). Of those 77 proteins, 19 were lower in abundance in obese versus lean, diabetic versus lean, or diabetic versus obese subjects, and 58 were greater in abundance by a factor of 2 in either obese or diabetic subjects versus lean control subjects. Of the 19 that were lower in abundance in insulin resistance, 9 were mitochondrial; of the 58 that were higher in abundance, only 3 were
Proteins assigned with 99% confidence in at least half (12 of 24 subjects)?

Combine into sets based on GO classifications or manually curation

Compute normalized average NSAF value for all proteins in a set for each individual in the three groups

Significant by analysis of variance (P < 0.05)?

Yes
- 21 sets (Supplemental Table 4)

No
- (no further analysis)

FIG. 2. Work flow of statistical analysis of protein sets.

mitochondrial (P < 0.002, Fisher exact probability test), including citrate synthase. Among the mitochondrial proteins that decreased by a factor of 2 but were not

TABLE 1
Subject characteristics

|          | Lean | Obese | Diabetic |
|----------|------|-------|----------|
| n        | 8    | 8     | 8        |
| Sex (F/M)| 4/4  | 4/4   | 4/4      |
| Age (years) | 37 ± 4 | 44 ± 3 | 48 ± 3*  |
| BMI (kg/m²) | 24.3 ± 0.8 | 31.6 ± 0.8† | 29.0 ± 1.1* |
| Body fat (%) | 26.8 ± 2.9 | 33.7 ± 2.8 | 34.2 ± 3.5 |
| M [mg/(kg · min)] | 8.2 ± 0.7 | 3.8 ± 0.2† | 1.6 ± 0.5† |
| Fasting blood glucose (mg/dl) | 94 ± 5 | 97 ± 1 | 148 ± 25† |
| A1C (%) | 4.8 ± 0.2 | 5.1 ± 0.2 | 8.3 ± 1.1† |
| Insulin (µU/ml) | 4.9 ± 0.4 | 12.6 ± 3.4† | 9.7 ± 2.9 |

Data are means ± SE. *P < 0.05, †P < 0.01 vs. lean control subjects.

M, rate of glucose metabolism.

FIG. 3. Linearity of the relationships between spectral abundance factors observed when 30 and 120 µg protein were analyzed, as described in RESEARCH DESIGN AND METHODS. Similar data obtained for 30 vs. 60 and 60 vs. 120 µg protein loading were compared (data not shown).
TABLE 2
Proteins differing significantly among groups

| Protein name | Lean | Obese | Diabetic | Protein set assignment | Number of subjects with protein assigned | K-W Lean | Obese | Diabetic | Total spectra per group |
|--------------|------|-------|----------|------------------------|-----------------------------------------|---------|-------|---------|------------------------|
| HSP90 co-chaperone CDC37 | 0.22 ± 0.22 | 1.92 ± 0.50* | 0.99 ± 0.41 | 0.50 ± 0.41 | 0.02* | 1 | 6 | 5 | 3 | 18 | 11 |
| Myosin-15 | 0.10 ± 0.1 | 0.83 ± 0.21* | 0.54 ± 0.22* | 0.03 | 0.03 | 1 | 6 | 5 | 5 | 40 | 27 |
| 55-kDa protein; protein disulfide-isomerase A3 precursor | 0.29 ± 0.21 | 1.71 ± 0.61* | 0.66 ± 0.13 | 0.04§ | 0.05 | 2 | 6 | 7 | 4 | 22 | 9 |
| Cullin homolog 5 | 0.17 ± 0.08 | 0.78 ± 0.21 | 0.87 ± 0.28 | 0.05§ | 0.08 | 3 | 6 | 5 | 4 | 17 | 18 |
| N[G, N[G]-dimethylarginine dimethylaminohydrolase 1 | 0.80 ± 0.55 | 3.28 ± 0.58* | 2.32 ± 0.63 | 0.02 | 0.03 | 2 | 8 | 6 | 6 | 24 | 17 |
| Chaperonin containing TCP1, subunit 8 (theta) variant; T-complex protein 1 subunit theta | 0.78 ± 0.19 | 1.88 ± 0.51 | 2.50 ± 0.52* | 0.03‡ | 0.04 | 7 | 7 | 8 | 13 | 27 | 35 |
| T-complex protein 1 subunit delta | 0.85 ± 0.16 | 1.95 ± 0.39* | 2.00 ± 0.34* | 0.03 | 0.02 | 7 | 7 | 8 | 13 | 27 | 28 |
| Glutaminyl-TRNA synthetase | 0.32 ± 0.16 | 0.60 ± 0.20 | 1.30 ± 0.42* | 0.05 | 0.17 | 3 | 5 | 5 | 7 | 12 | 27 |
| Proteasome subunit beta type 3 | 0.78 ± 0.32 | 0.92 ± 0.37 | 2.05 ± 0.55* | 0.01 | 0.16 | 4 | 4 | 6 | 5 | 5 | 11 |
| Alpha actin-2 | 18.2 ± 3.3 | 10.6 ± 3.2* | 8.18 ± 1.22* | 0.04‡ | 0.05 | 8 | 8 | 8 | 508 | 282 | 195 |
| Cytochrome C oxidase polypeptide VIC precursor | 72.1 ± 15.1 | 38.2 ± 10.6* | 27.1 ± 5.9* | 0.03‡ | 0.10 | 7 | 8 | 7 | 166 | 74 | 57 |
| Coiled-coil-helix-coiled-helix domain-containing protein 3 | 5.57 ± 1.25 | 2.51 ± 0.56* | 2.07 ± 0.91 | 0.03 | 0.03 | 8 | 7 | 4 | 36 | 15 | 12 |
| Myozenin-1 | 6.65 ± 1.73 | 2.70 ± 1.78* | 1.56 ± 0.59 | 0.05‡ | 0.13 | 6 | 2 | 5 | 68 | 27 | 13 |
| Desmin; mutant desmin | 3.98 ± 0.96 | 1.45 ± 0.52* | 1.86 ± 0.56* | 0.04 | 0.07 | 7 | 5 | 6 | 62 | 21 | 24 |
| Ubiquinol-cytochrome C reductase complex polypeptide ubiquinone-binding protein QP-C | 21.4 ± 5.70 | 4.03 ± 2.70‡ | 4.81 ± 2.10† | 0.006* | 0.04 | 6 | 2 | 4 | 57 | 12 | 11 |

Data are for NSAF values × 10,000 and are means ± SE. P value listed is for overall ANOVA (PANOVA) and Kruskal-Wallis test (PK-W) among groups. Total spectra = sum of spectra across eight subjects in each group. Individual group a posteriori comparisons: *P < 0.05, ‡P < 0.01 vs. lean control subjects, by a posteriori tests after ANOVA. †Variances not homogeneous.

statistically significant by ANOVA were five additional subunits involved in the electron transport chain, including the ATP synthase β-subunit, and two additional proteins involved in import of proteins into mitochondria, mitochondrial import inner membrane translocase subunit TIM13, and sorting and assembly machinery component homolog SAM50.

Regarding proteins that were increased in insulin resistance, nine proteins were greater by at least twofold (obese versus lean and/or diabetic versus lean and also) and also significant by ANOVA. Of those nine, three were chaperones or co-chaperones (HSP90 co-chaperone CDC37, T-complex protein 1 θ (TCP1 θ), and T-complex protein 1 δ (TCP1 δ). HSP90 co-chaperone CDC37 was increased by a factor of four- to eightfold in insulin resistant muscle, while the TCP1 subunits both were increased two- to threefold (Fig. 4C). Two proteins that significantly increased are involved in protein ubiquitination and degradation (cullin homolog 5 and proteasome subunit beta type 3). One protein, myosin-15, is a molecular motor that was increased four- to eightfold in insulin resistance. Another protein, protein disulfide isomerase a3, which stabilizes proteins with disulfide bonds, was increased two- to fourfold in insulin resistance. Of note is N[G, N[G]-dimethylarginine dimethylaminohydrolase 1, which was higher by fourfold in obesity and nearly threefold in the diabetic group.

Among the 77 proteins that were altered by a factor of 2 in insulin-resistant subjects but that were not statistically significantly different, 58 were greater in abundance in either obese or diabetic, or both, versus lean control subjects. The 58 that were greater included a number of proteins related to those that did increase significantly by ANOVA. Perhaps the most pronounced example of this is the TCP1 proteins, of which TCP1 α and η subunits were increased by twofold or more. NSAF values for the TCP1 subunits that were assigned in at least half the subjects are given in Fig. 4C. In addition a number of proteasome subunits also were higher by at least twofold in insulin resistance, including 26S proteasome regulatory subunit 3, 26S proteasome regulatory subunit 4, proteasome subunit beta type 4, proteasome 26S subunit 11 variant, isoform 1 of proteasome subunit alpha type 7, and 26S proteasome regulatory subunit 7. NSAF values for the proteasome subunits are shown in Fig. 4D. Other proteins, related to the cytoskeleton or cell structure that were at least twofold greater but were not significant by ANOVA, included actin, alpha actinin-3, kinesin, and tropomisin.

Protein set analysis. Patterns of changes in proteins were analyzed by comparing differences in abundance of sets of proteins included in various gene ontology (GO) classifications and selected hand-curated sets (electron transport chain complexes I–V and TCP1 subunits). Only sets containing five or more proteins were analyzed to avoid undue influence of changes in only one or two proteins in a set. Supplemental Table 4 shows representative sets that were significantly different (P < 0.05 by
ANOVA) between obese and lean or diabetic and lean subjects. GO classifications involving mitochondrial compartments or functions, such as electron transport, were significantly lower in abundance in obese and diabetic muscle. GO classifications where protein abundance was greater involved apoptosis, protein phosphorylation, reactive oxygen species metabolism, and microtubule/cytoskeleton function. Results for manually curated sets comprising complexes I–V of the respiratory chain are shown in Fig. 5. Compared with lean control subjects, complex I, III, IV, and V proteins showed a graded decrease from lean to obese nondiabetic subjects to patients with type 2 diabetes. Differences in complexes III and IV achieved statistical significance (P < 0.05).

The program GEDI was used to visualize groups of proteins that had similar relative protein abundance differences compared with a global median value (Fig. 6). This analysis showed seven major regions with similar patterns of protein abundance among the three groups. Areas 3 and 5 contain many mitochondrial oxidative phosphorylation proteins (lower in insulin resistance), whereas areas 1 and 2 contain a number of proteins involved in protein degradation (higher in insulin resistance). A list of proteins in the numbered regions is given in supplemental Table 5.

FIG. 4. Relative changes in abundance in mitochondrial proteins (A), cytoskeletal and structural proteins (B), TCP1 (chaperonin) complex proteins (C), and proteins involved in proteolytic process or protein modification leading to degradation (D). Data are given as means ± SE NSAF values for lean control (●), obese nondiabetic (□), and type 2 diabetic participants (□). All NSAF values were multiplied by 10,000 for purposes of presentation. *P < 0.05, **P < 0.01 vs. lean control subjects (see RESEARCH DESIGN AND METHODS for details). All proteins shown were different among groups by ANOVA (at least P < 0.05) or differed by at least a factor of 2 among at least two groups. Numbers in parentheses as follows indicate the number of subjects with that protein assigned (non–zero-NSAF) for lean, obese, and diabetic subjects, respectively: COX6C, cytochrome c oxidase subunit 6c (7, 8, 7); UQCRQ, ubiquinol-cytochrome C reductase complex ubiquinone-binding protein QP-C (6, 2, 4); CHCHD3, coiled-coil helix coiled-coil helix domain containing protein 3 (8, 7, 4); TCP1, T-complex protein 1 delta (7, 7, 8), theta (7, 7, 8), eta (6, 6, 7), etc (2, 4, 6); Beta 3, proteasome subunit beta type 3 (4, 4, 6); Alpha 2, proteasome subunit alpha type 2 (4, 8, 7); 26S reg. 3, 26S proteasome regulatory subunit 3 (4, 3, 6); 26S reg. 4, 26S proteasome regulatory subunit 4 (3, 6, 4); Beta 4, proteasome subunit beta type 4 (4, 6, 6); 26S sub. 11, 26S proteasome subunit 11 (4, 6, 7); 26S reg. 7, 26S regulatory subunit 7 (5, 5, 7).

FIG. 5. Results of analysis of manually curated protein sets for complexes I–V of the electron transport chain (ETC). Data are given as means ± SE scaled NSAF values for lean control (●), obese nondiabetic (□), and type 2 diabetic participants (□). *P < 0.05, **P < 0.01 vs. lean control subjects (see RESEARCH DESIGN AND METHODS for details).
Proteins differing in abundance between diabetic and obese nondiabetic subjects. To gain insight into alterations in protein abundance due to diabetic status, we examined proteins that differed by a factor of 2 between the diabetic and obese groups. Proteins involved in mitochondrial function in general were lower in the diabetic group than in the obese nondiabetic subjects. HSP90 co-chaperone CDC37 and \( N^G \), \( N^G \)-dimethylarginine dimethylaminohydrolase-1 were lower in diabetic versus obese subjects, but still greater in abundance relative to lean control individuals.

**Immunoblot analysis of desmin and alpha actinin-2.** We performed immunoblots for desmin and alpha actinin-2 protein abundance using the remaining lysate from seven of the eight subjects in each of the three groups of lean, obese, and diabetic volunteers. Results from densitometry analysis of these proteins were expressed relative to the 78-kDa protein PDLIM6, which was found not to differ among the groups in abundance in the mass spectrometry analysis \( (P = 0.44, \text{protein assigned in all subjects in all three groups; supplemental Table 1}) \) or immunoblot analysis. The results from quantification of these blots mirrored the results using our NSAF method and statistical analysis (Fig. 7). The correlation coefficients between NSAF values and blot values were 0.80 \( (P < 0.0001) \) and 0.69 \( (P < 0.001) \) for alpha actinin-2 and desmin, respectively.

**FIG. 6.** Heat maps clustering proteins into groups with similar abundance relative to a global median, obtained using the program GEDI. A total of 400 proteins with spectra obtained in at least 12 of 24 subjects were analyzed. Proteins assigned by the GEDI algorithm to areas 1–7 are given in supplemental Table 5. Proteins were grouped based on their pattern of changes relative to a global median, where shades of blue indicate proteins decreased relative to overall median, green indicates little change, and shades of yellow, orange, and red indicate proteins with increased abundance relative to the global median. GEDI maps cluster proteins into “neighborhoods” with other proteins that display similar patterns of changes among the groups; axes are unit-less. (A high-quality color digital representation of this figure is available in the online issue.)

**FIG. 7.** Immunoblot analysis comparing abundance of desmin (A) and alpha actinin-2 (B) content in skeletal muscle biopsies from lean (○), obese nondiabetic (■), and type 2 diabetic (●) \( (n = 7 \text{ each}) \). Density values from blots were expressed relative to PDLIM6 protein determined on the same blots and were normalized for each protein to the mean value of the lean controls, expressed as 100%. Representative blots from lean, obese, and diabetic subjects (two of each) are shown in the inset for both proteins. Data are shown as means ± SE. \( *P < 0.05 \) vs. lean control values.
DISCUSSION

A wide array of abnormalities is associated with skeletal muscle insulin resistance (3–6,8,9). Because investigations of these effects often have focused on a particular protein or biochemical pathway, it has been problematic to discern larger patterns of differences between insulin-resistant and healthy muscle. A more global approach can be useful for identifying novel patterns of changes and lead to new focused hypotheses. Global analyses of mRNA expression in insulin-resistant muscle by microarray analysis revealed a pattern of reduced expression of genes involved in mitochondrial function and metabolism (7–9). These results helped to define mitochondrial dysfunction as a characteristic of insulin resistance. However, mRNA expression levels may not reflect protein abundance, providing a compelling reason for a global analysis of protein abundance changes in insulin-resistant muscle. Therefore, the present study was undertaken to provide data that would serve to generate new hypotheses regarding insulin resistance. To accomplish this, we used one-dimensional SDS-PAGE gels as the first dimension of separation in a multi-dimension, mass spectrometry–based process for protein assignment, with quantification using the NSAF method (21–23).

Previous studies of mRNA expression levels revealed a pattern of decreased expression of nuclear-encoded genes coding for proteins involved in mitochondrial function in insulin-resistant muscle (7–9). The present results extend this to show that the abundance of proteins involved in many mitochondrial functions also is reduced. Lending further evidence for a generalized decrease in mitochondrial protein abundance were results of analysis of protein sets grouped by GO classification. Of the 15 GO sets that were significantly reduced in insulin-resistant subjects, 13 represented mitochondrial proteins. When electron transport chain complex components were curated into individual subunits, all but complex II proteins were reduced in insulin-resistant subjects, with complexes III and IV achieving statistical significance (P < 0.05) and complex I being marginally significant (P = 0.066). These results provide confirmation of the reports of decreased number or size of mitochondria in skeletal muscle from insulin-resistant subjects (29,30). Based on the current findings, those results can be extended to conclude that there is a widespread decrease in mitochondrial proteins, including components of the respiratory chain and protein import machinery.

Results from the present studies also show changes in abundance of several proteins involved in structure or function of the cytoskeleton. A significantly lower abundance was found of the actin capping and Z-disk component protein alpha actinin-2. Myogenin-1, which binds to alpha actinin (31), also was lower in abundance, as was a major intermediate filament component, desmin. On the other hand, a set of microtubule-related proteins, including tubulins and kinesins, was significantly increased in insulin resistance. Previous results have shown the essential nature of interactions of mitochondria with the cytoskeleton for normal mitochondrial function (32–34). It is tempting to speculate that a relationship exists between altered mitochondrial function and protein abundance and abnormalities in the abundance of cytoskeletal elements, particularly intermediate filament and Z-disk components, in insulin-resistant muscle. Intermediate filaments in skeletal muscle integrate force transduction between the sarcomere and extracellular matrix, through proteins such as integrins and the dystroglycan complex (35,36). Moreover, intermediate filaments organize organelles in skeletal muscle, including mitochondria, and are involved in regulating their function (35). We previously showed inflammatory-like extracellular matrix changes in insulin-resistant muscle (37–39). The present results provide the basis for a new hypothesis regarding the mechanisms of insulin resistance in muscle, namely, that changes in the extracellular matrix might lead to altered mitochondrial function by means of altered mechano-signal transduction produced by changes in intermediate filament protein abundance. A scenario connecting the extracellular matrix and mitochondrial function has been described for Bethlem muscular dystrophy, a collagen 6 mutation in humans (40). This hypothesis must be tested in further studies.

Another novel change observed in the present study is the increase in abundance of chaperonin proteins, namely T-complex proteins (TCP-1) and HSP90 co-chaperone CDC37. TCP-1 is a mammalian cytosolic chaperonin required for proper folding of proteins involved in cytoskeletal formation and contractile activity (41,42). Eight of the 10 subunits of TCP-1 were assigned in this study. Of these, two (TCP-1 δ and θ) were significantly increased in one or both groups of insulin-resistant subjects, and two others, TCP-1 α and η, were increased by at least twofold in one of the insulin-resistant groups, but were not significant by ANOVA. The expression of TCP-1 subunits θ and α is under coordinated control of extracellular signal-regulated kinase (ERK)-1/2 signaling (41), and a number of TCP-1 subunits have coordinately regulated expression (42). These findings are consistent with reports that MAP kinase/ERK signaling is preserved or increased in insulin-resistant skeletal muscle (3,4). In insulin resistance, plasma insulin concentrations are increased as a compensatory effort to normalize glucose metabolism. Because ERK signaling is preserved or increased in insulin-resistant muscle, in the setting of hyperinsulinemia, ERK signaling is likely to be increased. The present finding of a coordinated increase in TCP-1 abundance is the first reported potential consequence of the increase in ERK signaling in insulin-resistant muscle. The increased abundance of the major cytosolic chaperonin complex TCP-1 may be related mechanistically to the increases in abundance of several cytoskeletal and structural proteins also found in this study.

Another protein that showed an increase in abundance in insulin-resistant muscle was N⁴,N⁶-dimethylarginine dimethylaminohydrolase-1. The function of this enzyme is to metabolize N⁴,N⁶-dimethylarginine, also called asymmetric arginine, or ADMA (43). ADMA is a naturally occurring inhibitor of NO synthase (44) and is increased in plasma of individuals with hypercholesterolemia, hypertension, and type 2 diabetes (45–47). The increase in abundance of N⁴,N⁶-dimethylarginine dimethylaminohydrolase-1 in insulin-resistant muscle suggests that there may be a compensatory response in muscle in an effort to reduce ADMA.

The present findings also show that there are increases in the abundance of a number of proteins involved in proteasome function in insulin-resistant muscle. Although poorly controlled diabetic subjects are characterized by increased rates of proteolysis (48), it is less clear that a general increase in protein turnover characterizes insulin-resistant muscle, although some conditions associated with insulin resistance are also associated with increased...
protein degradation, such as aging or type 1 diabetes (49,50). On a molecular level of analysis, Wang et al. (51), using insulin-resistant mice, showed that increased proteasome activity could be attributed to decreased signaling through IRS-1 and Akt, which occurs in insulin-resistant human muscle (3,4).

It should be noted that the diabetic subjects were on average 11 years older than the lean control subjects, although they were not significantly older than the obese nondiabetic subjects. All participants were middle-aged and very sedentary, suggesting that there are no age-related differences in physical activity. Moreover, gene expression studies over the age range of 20 to >80 years show few changes, and those who were observed had a very slow rate of change over age (52). Another major caveat of the results of this study is that not all proteins were assigned in each subject in each group. Given this caveat, and the limitations of statistical analysis of large datasets where some assumptions of statistical tests employed may not be met in every case, it must be stressed that the results from this study should serve as a starting point for additional, more focused studies designed to test hypotheses that might be generated by these findings.

In summary, the current results suggest that there is a wide array of changes in protein abundance in insulin-resistant skeletal muscle. Several potential themes emerge that must be addressed in future studies. These themes include lower abundance of mitochondrial proteins, alterations in abundance of proteins involved in cytoskeletal structure and function, and higher abundance of proteasome subunits and molecular chaperones. These changes provide new information about potential relationships among various pathways that may converge to create insulin resistance.

ACKNOWLEDGMENTS

This study was supported in part by National Institutes of Health Grants R01DK47936 (L.J.M.), R01DK66483 (L.J.M.), and R01DK081750 (Z.P.Y.) and by the American Diabetes Association.

No potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form at the 68th Scientific Sessions of the American Diabetes Association, San Francisco, California, 6–10 June 2008.

The authors gratefully acknowledge the technical assistance of Kenneth Kirschner and especially thank the individuals who volunteered for the study.

REFERENCES

1. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver: a colusion responsible for NIDDM. Diabetes 1988;37:667–687
2. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yenomitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007;104: 12387–12394
3. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mardanaro Lj. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311–320
4. Krook A, Bjornholm M, Galuska D, Jiang X, Fahnlin R, Myers MG Jr, Wallberg-Henriksson H, Zierath JR. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 2000;49:284–292
5. Kelley DE, Mokan M, Mardanaro LJ. Intracellular defects in glucose metabolism in obese patients with NIDDM. Diabetes 1992;41:698–706
6. Pendergrass M, Koval J, Vogt C, Yki-Jarvinen H, Iozzo P, Pepek R, Ardehali H, Prinz R, Granner D, DeFronzo RA, Mandarino Lj. Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 1998;47:387–394
7. Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS. Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 2002;51:1913–1920
8. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstitis N, Daly MJ, Patterson N, Mesiroy JP, Golub TR, Tamayo P, Spiegelman B, Landers E, Hirschhorn JN, Alshuler D, Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267–273
9. Patti ME, Butte AJ, Crunkhorn S, Berrila R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saconnce R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mardanaro Lj. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRP1. Proc Natl Acad Sci U S A 2003;100:8466–8471
10. Befroy DE, Petersen KF, Dufour S, Mason GF, de Graaf RA, Rothman DL, Shulman GI. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes 2007;56:1376–1381
11. Bonaltd T, Straub T, Cox J, Kumar C, Becker PB, Mann M. Combined use of RNAI and quantitative proteomics to study gene function in Drosophila. Mol Cell 2008;31:762–772
12. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, Sato M, Bader JS, Lash AE, Minna JD, Pandey A, Varmus HE. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 2008;105:14112–14117
13. Ong SE, Blagoe B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. Stable isotopic labeling by amino acids in cultured primary neurons: application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling. Mol Cell Proteomics 2008;7:1067–1076
14. Donners MM, Verhuyten MJ, Bouweman PG, Mackinnon EC, Devreese B, Vanrobaeys F, Van Beunen J, Van den Akker LH, Daemen MJ, Heeneman S. Proteomic analysis of differential protein expression in human atherosclerotic plaque progression. J Pathol 2005;206:39–45
15. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, Sato M, Bader JS, Lash AE, Minna JD, Pandey A, Varmus HE. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 2008;105:14112–14117
16. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, Sato M, Bader JS, Lash AE, Minna JD, Pandey A, Varmus HE. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 2008;105:14112–14117
26. Hjellmand K, Yi Z, Hwang H, Bowen B, Lefort N, Flynn CR, Langlais P, Weintraub ST, Mandarino LJ. Characterization of the human skeletal muscle proteome by one-dimensional gel electrophoresis and HPLC-ESI-MS/MS. Mol Cell Proteomics 2008;7:257–267.

27. Yi Z, Bowen BP, Hwang H, Jenkinson CP, Coletta DK, Lefort N, Bajaj M, Kashyap S, Berria R, De Filippis EA, Mandarino LJ. Global relationship between the proteome and transcriptome of human skeletal muscle. J Proteome Res 2008;7:3230–3241.

28. Eichler GS, Huang S, ingber DE. Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles. Bioinformatics 2003;19:2321–2322.

29. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002;51:2044–2050.

30. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005;54:8–14.

31. Takada F, Vander Woude DL, Tong HQ, Thompson TG, Watkins SC, Kunkel LM, Beggs AH. Myozenin: an alpha-actinin- and gamma-filamin-binding protein of skeletal muscle Z lines. Proc Natl Acad Sci USA 2001;98:1595–1600.

32. Boldogh IR, Pon LA. Interactions of mitochondria with the actin cytoskeleton. Biochim Biophys Acta 2006;1763:450–462.

33. Frederick RL, Shaw JM. Moving mitochondria: establishing distribution of an essential organelle. Traffic 2007;8:1686–1675.

34. McKane M, Wen KK, Boldogh IR, Ramcharan S, Pon LA, Rubenstein PA. A mammalian actin substitution in yeast actin (H372R) causes a suppressible mitochondria/vacuole phenotype. J Biol Chem 2005;280:36494–36501.

35. Capetanaki Y. Desmin cytoskeleton: a potential regulator of muscle mitochondrial behavior and function. Trends Cardiovasc Med 2002;12:339–348.

36. Capetanaki Y, Bloch RJ, Kouloumenta A, Mavroidis M, Psarras S. Muscle intermediate filaments and their links to membranes and membranous organelles. Exp Cell Res 2007;313:2063–2076.

37. Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C, DeFronzo RA, Cusi K, Mandarino SJ, Finlayson J, DeFronzo RA, Jenkinson CP, Mandarino LJ. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem 2005;280:10290–10297.

38. Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Megighian A, Merlini L, Braggia P, Columbaro M, Volpin D, Bressan GM, Bernardi P, Bonaldo P. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat Genet 2003;35:367–371.

39. Yamazaki Y, Kubota H, Nozaki M, Nagata K. Transcriptional regulation of the cytosolic chaperonin theta subunit gene, Cctq, by Ets domain transcription factors Etk-1, Sap-1a, and Net in the absence of serum response factor. J Biol Chem 2003;278:30642–30651.

40. Kubota H, Yokota S, Yanagi H, Yura T. Structures and co-regulated expression of the genes encoding mouse cytosolic chaperonin CCT subunits. Eur J Biochem 1999;262:492–500.

41. Duran E, Lee HW, Kim S, Paik WK. Purification and characterization of protein methylase I (S-adenosylmethionine: protein-arginine methyltransferase; EC 2.1.1.23) from calf brain. Methods Cell Biol 1978;19:50–67.

42. Onozato ML, Tojo A, Leiper J, Fujita T, Palm F, Wilcox CS. Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 2008;57:172–180.

43. Boger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842–1847.

44. Goonasekera CD, Rees DJ, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901–909.

45. Lin KY, Ito A, Asagami T, Tsao PS, Chan JR, Tangphao O, Reaven GM, Cooke JP. Impaired nitric oxide synthase activity in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987–992.

46. Halvatsiotis P, Short KR, Biggerow M, Nair KS. Synthesis rate of muscle proteins, muscle functions, and amino acid kinetics in type 2 diabetes. Diabetes 2002;51:2395–2404.

47. Nair KS. Muscle protein turnover: methodological issues and the effect of aging. J Gerontol A Biol Sci Med Sci 1995;50:107–112.

48. Charlton M, Nair KS. Protein metabolism in insulin-dependent diabetes mellitus. J Nutr 1998;128:323S–327S.

49. Nair KS. Muscle protein turnover: methodological issues and the effect of aging. J Gerontol A Biol Sci Med Sci 1995;50:107–112.

50. Charlton M, Nair KS. Protein metabolism in insulin-dependent diabetes mellitus. J Nutr 1998;128:323S–327S.

51. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006;147:4160–4168.

52. Short KR, Vittone JL, Bigelow ML, Proctor DN, Rizza RA, Coenen-Schimke JM, Nair KS. Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity. Diabetes 2003;52:1888–1896.